Garde Capital’s Exact Sciences EXAS Stock Holding History

Garde Capital’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-5	Closed	-$266	–	441
2025 Q2	$266	Hold	5	–	–	﹤0.01%	772
2025 Q1	$217	Buy	+5	New	+$253	﹤0.01%	770

Other funds holding EXAS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Garde Capital's EXAS Position: Q3 2025 in Review

Garde Capital sold out of Exact Sciences (EXAS) in Q3 2025, closing a stake of 5 shares — an estimated $266 sold.

Garde Capital first reported a position in EXAS in Q1 2025 and held it in 2 quarters. The position peaked at $266 in Q2 2025. 568 funds tracked by Wall St. Rank hold EXAS as of Q3 2025.

Garde Capital reported no remaining Exact Sciences position as of Q3 2025 after selling out during the quarter.
Garde Capital sold 5 Exact Sciences shares in Q3 2025, an estimated $266.
Garde Capital first reported a position in Exact Sciences in Q1 2025 and held it in 2 quarters.
Garde Capital's Exact Sciences position peaked at $266 in Q2 2025.
568 funds tracked by Wall St. Rank held Exact Sciences as of Q3 2025.

Based on Garde Capital's 13F filing for Q3 2025, filed 16 Dec 2025.